Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of Deucravacitinib BMS-986165 in adolescents aged 12 to 17 years with moderate to severe plaque psoriasis. The study aims to assess the drugs effectiveness, safety, and how it behaves in the body. This phase 3 trial is designed as a randomized, double-blind, placebo-controlled investigation to provide clear evidence of the drugs impact in this younger population. Participants are randomly assigned to receive either Deucravacitinib or a placebo following specified dosing schedules. The study involves a parallel group design where the treatment is given on specified days. The trial will monitor participants closely over time to evaluate treatment responses and any side effects, especially focusing on improvements in psoriasis severity and skin condition. During the study, participants will have regular assessments including measurement of psoriasis severity by Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA, body surface area affected, itch severity, and quality of life. Safety monitoring includes checking for adverse events, laboratory tests, physical exams, vital signs, and vaccine antibody levels. The study also tracks growth and sexual maturation over up to five years, providing long-term data on drug safety and participant health.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the drug EI-001 in adults with non-segmental vitiligo, a condition causing skin depigmentation. This Phase 2 study aims to assess whether EI-001, a novel antibody that modulates the immune system to reduce inflammation, can improve vitiligo symptoms. Previous studies showed EI-001 to be tolerable and a potential treatment for immune diseases, supporting its further investigation. Participants will receive either EI-001 or a placebo through infusion. EI-001 is supplied as a sterile solution with a protein concentration of 10.0 mgmL, while the placebo is a sterile sodium chloride solution. The study compares the effects of EI-001 against placebo in a randomized, double-blind design to evaluate its efficacy and safety over the treatment period. During the study, participants will undergo assessments including evaluation of vitiligo extent using the Facial Vitiligo Area Scoring Index F-VASI at baseline and Week 24. Researchers will monitor changes in vitiligo symptoms, treatment response rates, and any adverse events through Week 32. The study requires participants to discontinue other vitiligo treatments and complete vaccination against zoster if needed, with total participation lasting through the treatment and follow-up periods.